Possibility of blood test parameters usage in the evaluation of COVID-19 patients’ inflammatory status
- Authors: Nekrasova L.A.1, Jain M.2, Gubenko N.S.2, Budko A.A.2, Samokhodskaya L.M.2, Orlova I.A.2, Kamalov A.A.2
-
Affiliations:
- Specialized Research and Educational Center of Novosibirsk State University
- Lomonosov Moscow State University
- Issue: Vol 13, No 1 (2022)
- Pages: 14-21
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/80111
- DOI: https://doi.org/10.17816/clinpract80111
- ID: 80111
Cite item
Full Text
Abstract
Background: C-reactive protein (CRP) is a key laboratory biomarker for anti-inflammatory treatment initiation. Unfortunately, biochemical blood analyzers are not always easily accessible in medical institutions located far from major regional health facilities.
Aim: To develop an approach for inflammatory status estimation based on blood test results in patients with COVID-19 in cases with limited laboratory equipment availability.
Methods: The present retrospective study included 423 patients (male 54.6%; female 45.4%; mean age 59.1 years) receiving hospital treatment due to COVID-19 in Medical Research and Educational Center of Lomonosov Moscow State University from April 21st to June 13th 2020. All patients donated blood for full biochemistry and hematology testing and underwent chest computer tomography (CT).
Results: CRP levels (>60 mg/L) qualitative estimation model was developed based on hematologic test results. It included erythrocyte sedimentation rate and neutrophils to lymphocytes ratio. According to the results of Receiver Operating Characteristic (ROC) analysis present model was characterized by sensitivity of 70.2%, specificity of 74.6%, and area under the ROC-curve of 0.781. Comparison of key clinical parameters reflecting COVID-19 severity, such as length of hospitalization, lung damage at CT (hospital admission and discharge), revealed statistically significant difference between groups with routinely measured CRP levels ≤60 mg/L and >60 mg/L for all the above-mentioned parameters (p <0.05). These differences remained significant when measured CRP levels were substituted with estimated CRP values, indicating interchangeability of these approaches to CRP levels determination, regarding clinically important parameters.
Conclusions: Presented model for inflammatory status estimation based on hematologic test results might be used to overcome clinical challenges in cases with limited laboratory equipment availability.
Full Text
##article.viewOnOriginalSite##About the authors
Ludmila A. Nekrasova
Specialized Research and Educational Center of Novosibirsk State University
Email: l.nekrasova@nsu.ru
ORCID iD: 0000-0002-5161-8666
SPIN-code: 5609-3840
Russian Federation, Novosibirsk
Mark Jain
Lomonosov Moscow State University
Author for correspondence.
Email: jain-mark@outlook.com
ORCID iD: 0000-0002-6594-8113
SPIN-code: 3783-4441
junior researcher of the Laboratory Diagnostics Department
Russian Federation, 27/10, Lomonosovsky prospect, Moscow, 119234Nikita S. Gubenko
Lomonosov Moscow State University
Email: gubenkons@icloud.com
ORCID iD: 0000-0001-5723-4367
student of the Faculty of Fundamental Medicine
Russian Federation, MoscowAnton A. Budko
Lomonosov Moscow State University
Email: anton-budko@mail.ru
ORCID iD: 0000-0002-7362-176X
post-graduate student of the Faculty of Fundamental Medicine
Russian Federation, MoscowLarisa M. Samokhodskaya
Lomonosov Moscow State University
Email: slm@fbm.msu.ru
ORCID iD: 0000-0001-6734-3989
SPIN-code: 5404-6202
MD, PhD, Associate Professor, head of the Laboratory Diagnostics Department
Russian Federation, MoscowIana A. Orlova
Lomonosov Moscow State University
Email: 5163002@bk.ru
ORCID iD: 0000-0002-8160-5612
SPIN-code: 3153-8373
MD, Dr. Sci. (Med.), PhD, Assistant Professor, head of the age-related diseases department
Russian Federation, MoscowArmais A. Kamalov
Lomonosov Moscow State University
Email: priemnaya@mc.msu.ru
ORCID iD: 0000-0003-4251-7545
SPIN-code: 6609-5468
MD, Dr. Sci. (Med.), Professor, academician of the Russian Academy of Sciences
Russian Federation, MoscowReferences
- Who.int [Internet]. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 [updated 2021, August 14; cited 2021, August 14]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
- Worldometers.info [Internet]. American Library Association. COVID-19 Coronavirus Pandemic [updated 2021, August 14; cited 2021, August 14]. Available from: https://www.worldometers.info/coronavirus/.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi: 10.1093/cid/ciaa248
- Ragab D, Eldin HS, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
- Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta. 2020;509:91–94. doi: 10.1016/j.cca.2020.06.013
- Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504. doi: 10.1016/j.intimp.2020.106504
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). Минздрав России; 2020.
- Mareev VY, Orlova YA, Pavlikova EP, et al. Steroid pulse-therapy in patients with coronAvirus Pneumonia (COVID-19), sYstemic inFlammation and Risk of vEnous thRombosis and thromboembolism (WAYFARER Study) [In English, Russian]. Kardiologiia. 2020;60(6):15–29. doi: 10.18087/cardio.2020.6.N1226
- Yang P, Ding Y, Xu Z, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. MedRxiv. 2020. doi: 10.1101/2020.02.28.20028068
- Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35. doi: 10.1016/S0140-6736(20)30305-6
- Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020. doi: 10.1101/2020.02.10.20021832
- Nhc.gov.cn [Internet]. Disease Control and Prevention Bureau of China. Interpretation of New Coronavirus Pneumonia Prevention and Control Plan (Fifth Edition) [updated 2021, August 14; cited 2021, August 14]. Available from: http://www.nhc.gov.cn/jkj/s3578/202002/dc7f3a7326e249c0bad0155960094b0b.shtml.
- Henry BM, de Oliveira MH, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. doi: 10.1515/cclm-2020-0369
- Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatric Pulmonology. 2020;55:1169–1174. doi: 10.1002/ppul.24718
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5
- Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399. doi: 10.1080/10408363.2020.1770685
- Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging. 2020;12(7):6037–6048. doi: 10.18632/aging.102999
- Lu J, Sun PD. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. J Biol Chem. 2020;295(52):18579. doi: 10.1074/jbc.ra120.015303
- Khanna K, Raymond W, Charbit AR, et al. Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies. BioRxiv. 2020. doi: 10.1101/2020.12.08.415505
- Smilowitz NR, Kunichoff D, Farshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270–2279. doi: 10.1093/eurheartj/ehaa1103
- Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–334. doi: 10.1016/j.medmal.2020.03.007
- Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virology. 2020;92(7):856–862. doi: 10.1002/jmv.25871